Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases

Varman T. Samuel1,4,* and Gerald I. Shulman1,2,3,*

1Department of Medicine
2Department of Cellular and Molecular Physiology
3Howard Hughes Medical Institute
4Yale University School of Medicine, New Haven, CT 06516, USA
*Correspondence: varman.samuel@yale.edu (V.T.S.), gerald.shulman@yale.edu (G.I.S.)

http://dx.doi.org/10.1016/j.cmet.2017.08.002

NAFLD is closely linked with hepatic insulin resistance. Accumulation of hepatic diacylglycerol activates PKC-ε, impairing insulin receptor activation and insulin-stimulated glycogen synthesis. Peripheral insulin resistance indirectly influences hepatic glucose and lipid metabolism by increasing flux of substrates that promote lipogenesis (glucose and fatty acids) and gluconeogenesis (glycerol and fatty acid-derived acetyl-CoA, an allosteric activator of pyruvate carboxylase). Weight loss with diet or bariatric surgery effectively treats NAFLD, but drugs specifically approved for NAFLD are not available. Some new pharmacological strategies act broadly to alter energy balance or influence pathways that contribute to NAFLD (e.g., agonists for PPAR γ, PPAR α/β, FXR and analogs for FGF-21, and GLP-1). Others specifically inhibit key enzymes involved in lipid synthesis (e.g., mitochondrial pyruvate carrier, acetyl-CoA carboxylase, stearoyl-CoA desaturase, and monoacyl- and diacyl-glycerol transferases). Finally, a novel class of liver-targeted mitochondrial uncoupling agents increases hepatocellular energy expenditure, reversing the metabolic and hepatic complications of NAFLD.

Introduction
Over the past century, industrialized nations have undergone an epidemiological transition. Better policies and novel therapies prevent or cure many once-fatal infectious diseases (e.g., the global eradication of smallpox and eradication of malaria and polio from many countries). But now non-communicable diseases threaten modern societies. In many instances, the increasing burden of non-communicable disease is associated with rising rates of obesity. For the first time, life expectancy in the United States has decreased, and can be partly attributed to obesity-related “metabolic diseases,” including type 2 diabetes (T2D), kidney disease, stroke, and heart disease (Xu et al., 2016).

The transition from infectious to metabolic disease is apparent in the shifting epidemiology of liver diseases. Vaccines and therapies now prevent or cure many forms of viral hepatitis. However, nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as the most common chronic liver disease (Younossi and Henry, 2016). NAFLD is associated with obesity and encompasses a range of pathologies from steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. NAFLD also increases the risk of hepatocellular carcinoma (HCC). The incidence of HCC is rising, and NAFLD may account for up to 25% of these cases in Westernized countries, though this association may be even higher (Michelotti et al., 2013). And the prevalence of NASH in patients awaiting liver transplant has risen dramatically over the last decade, surpassing alcoholic liver disease and second only to chronic hepatitis C (Wong et al., 2015). The liver plays key roles in glucose and lipoprotein metabolism. Unsurprisingly, NAFLD is a risk factor for many metabolic diseases, including T2D (Lallukka and Yki-Järvinen, 2016) and cardiovascular disease (Targher et al., 2010). The presence of diabetes mellitus can also increase the risk of liver diseases (Raff et al., 2015). Thus, NAFLD is a common preceding condition for both clinically important liver and metabolic diseases.

Insulin Regulation of Hepatic Glucose and Lipid Metabolism
A healthy liver has remarkable metabolic plasticity. Over the course of a day, hepatocytes readily shift back and forth between the disparate metabolic tasks of energy storage and supply. These transitions are seamless; multiple factors including nutrients, pancreatic and enteric hormones, and neural inputs precisely manage substrate availability for the entire body. A complete accounting for all the pathways that regulate hepatic lipid and glucose metabolism is beyond the scope of this review and was recently reviewed in greater detail elsewhere (Samuel and Shulman, 2016). We also will not discuss mechanisms governing inflammation and fibrosis in the progression of NAFLD to NASH and cirrhosis (reviewed in detail in Fuchs and Schnabl, 2016). Instead, in this review, we focus on NAFLD as a nexus of metabolic disease and liver disease. We review how insulin normally regulates hepatic glucose and lipid metabolism, how the development of NAFLD impacts hepatic insulin action, and how therapies that treat NAFLD may also impact hepatic insulin action and the development of NASH and T2D.

Insulin regulates hepatic glucose and lipid metabolism by both direct and indirect mechanisms. Following a meal, the relatively high concentrations of insulin within the portal vein (~3x peripheral vein) directly activate hepatic insulin receptor tyrosine kinase (IRTK) activity, initiating a coordinated relay of intracellular signals (Figure 1) (Samuel and Shulman, 2012).

Please cite this article in press as: Samuel and Shulman, Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases, Cell Metabolism (2017), http://dx.doi.org/10.1016/j.cmet.2017.08.002
These include 3-phosphoinositide-dependent kinase-1 (PDK1) and mechanistic target of rapamycin complex 2 (mTORC2) (Guertin and Sabatini, 2007), which converge on Akt phosphorylation (Alessi et al., 1997; Guertin and Sabatini, 2007; Stephens et al., 1998). This model has been used to account for the mechanisms by which direct insulin action suppresses hepatic glucose production via (1) activation of glycogen synthase (Petersen et al., 1998b) and (2) lowering expression of gluconeogenic enzymes via phosphorylation and nuclear exclusion of FOXO1 (Nakae et al., 2001). But this transcriptional regulation does not fully account for the changes in gluconeogenesis; the changes in protein expression lag behind the changes in mRNA and hepatic glucose production seen after an acute insulin stimulus.

Portal insulin acts on liver insulin receptors to directly activate glycogen synthesis and de novo lipogenesis.

Peripheral insulin indirectly regulates hepatic glucose and lipid metabolism by: 1) inhibiting adipose lipolysis 2) promoting muscle glucose uptake

Figure 1. Insulin Action Regulates Hepatic Glucose and Lipid Metabolism via Direct and Indirect Mechanisms

The liver is exposed to a high concentration of insulin via the portal vein. Binding of insulin to the insulin receptor tyrosine kinase (IRTK) activates Akt2 and acutely activates glycogen synthase. Direct hepatic insulin action will also decrease transcription of gluconeogenic enzymes via inactivation of FOXO1, followed later by a decrease in the protein expression of these enzymes. Insulin signaling also promotes activation and expression of SREBP1. Peripheral insulin action also indirectly impacts hepatic glucose and lipid metabolism. In skeletal muscle, insulin activates glucose transport and glycogen synthesis, limiting glucose as a substrate for hepatic metabolism. In adipose tissue, insulin acts to promote glucose uptake and inhibit lipolysis. The latter decreases fatty acid and glycerol flux. The decrease in fatty acid flux decreases hepatic mitochondrial acetyl-CoA, an allosteric activator of pyruvate carboxylase. The decrease in glycerol flux will also decrease gluconeogenesis by constraining the influx of this substrate. The decrease in fatty acid flux will also decrease esterification of adipose-derived fatty acids.

These include 3-phosphoinositide-dependent kinase-1 (PDK1) and mechanistic target of rapamycin complex 2 (mTORC2) (Guertin and Sabatini, 2007), which converge on Akt phosphorylation (Alessi et al., 1997; Guertin and Sabatini, 2007; Stephens et al., 1998). This model has been used to account for the mechanisms by which direct insulin action suppresses hepatic glucose production via (1) activation of glycogen synthase (Petersen et al., 1998b) and (2) lowering expression of gluconeogenic enzymes via phosphorylation and nuclear exclusion of FOXO1 (Nakae et al., 2001). But this transcriptional regulation does not fully account for the changes in gluconeogenesis; the changes in protein expression lag behind the changes in mRNA and hepatic glucose production seen after an acute insulin stimulus.

More than 50 years ago, Levine and Fritz (1956), and subsequently Prager et al. (1987), proposed that insulin inhibited hepatic glucose production indirectly, via action at peripheral sites. Subsequent studies (Lewis et al., 1996; Rebrin et al., 1996) postulated that these indirect effects of insulin to suppress hepatic glucose production were mediated by suppression of white adipose tissue (WAT) lipolysis, which Bergman hypothesized reflected transendothelial transport of insulin into the interstitium and subsequent insulin action (Bergman, 1997). More recently, Perry et al. provided an alternative molecular mechanism for this indirect effect of insulin to suppress hepatic gluconeogenesis and hepatic glucose production (Perry et al., 2015a). Perry et al. showed that insulin suppression of WAT lipolysis decreases hepatic acetyl-CoA content (an allosteric activator of pyruvate carboxylase [PC]), which in turn reduces PC activity and PC flux (Figure 1) (Perry et al., 2015a). Inhibiting lipolysis also curtails glycerol delivery to the liver, reducing the conversion of glycerol to glucose by a substrate push mechanism (Perry et al., 2014; Previs et al., 1999). As a proof of this concept, atglistatin, an inhibitor of adipose triglyceride lipase, reduced rates of hepatic gluconeogenesis in normal chow-fed rats; insulin-resistant, high-fat-fed rats; and rats treated with an antisense oligonucleotide (ASO) to knock down hepatic and adipocyte IRTK (Perry et al., 2015a) by both 1) reducing hepatic acetyl-CoA content...
with resulting reductions in pyruvate carboxylase activity/flux and 2) reducing glycerol delivery to liver and its contribution to gluconeogenesis. However, the high concentration of insulin via the portal vein can still regulate hepatic glucose flux independently of prevailing fatty acid concentrations, neural action, or glucagon (Edgerton et al., 2017). This acute and direct action of insulin may be more focused on Akt2-mediated regulation of hepatic glycogen metabolism (Wan et al., 2013). These direct effects of insulin on hepatic glucose production would be expected to predominate in a hepatic glycogen-replete state following short-term fasting, whereas the indirect effects of insulin (i.e., suppression of WAT lipolysis) would be expected to predominate the regulation of hepatic glucose production under glycogen-depleted states such as long-term fasting when gluconeogenesis is the major contributor to hepatic glucose production.

Insulin regulation of hepatic lipid metabolism also involves both direct (hepatic) and indirect (extrahepatic) pathways (Figure 1) (though multiple hormonal, neural, and metabolic signals modulate hepatic lipid metabolism). Direct hepatic insulin action activates SREBP1c by increasing mRNA expression and proteolytic cleavage of the SREBP1c precursor protein into a mature nuclear transcription factor (Brown and Goldstein, 2008). Insulin signaling also increases the activity of mTORC1, which regulates SREBP1c mRNA expression (Li et al., 2010) and processing (Peterson et al., 2011). SREBP1c is also regulated independently of insulin, as demonstrated by induction of SREBP1c after feeding in mice lacking hepatic insulin receptors (Haas et al., 2012). Other factors also influence hepatic de novo lipogenesis (DNL). For example, monosaccharides also recruit other transcription factors, including ChREBP (Erion et al., 2013; Uyeda and Repa, 2006), PPARγ coactivator 1-α (Nagai et al., 2009), and liver X receptor (Blümbel et al., 2015), to activate lipogenesis.

Peripheral insulin action indirectly regulates hepatic lipids and synthesis. Hepatic fatty acids may be derived from triglycerides in lipid particles (e.g., chylomicron remnants and LDL). The liver also clears fatty acids from the circulation, a major source of hepatic triglycerides (Donnelly et al., 2005). Insulin influences each of these inputs via extra-hepatic actions. For example, insulin activates lipoprotein lipase (LpL) at peripheral sites, promoting the hydrolysis of triglycerides and uptake of fatty acids into adipose and muscle. Insulin also suppresses adipose lipolysis and influences the amount of fatty acyl-CoA available for esterification into hepatic triglyceride. Vatner et al. demonstrated that hepatic triglyceride synthesis could be driven by substrate (fatty acids) availability, independent of changes in hepatic insulin signaling (Vatner et al., 2015). They tested this in awake normal rats; high-fat-fed, insulin-resistant rats; and insulin receptor 2-ΔO-methoxyethyl chimeric ASO-treated rats infused with varying concentrations of lipid and insulin. Rates of fatty acid esterification into hepatic triglyceride were dependent on the rate of fatty acid delivery to the liver and independent of hepatocellular insulin signaling. In contrast, de novo hepatic lipogenesis was insulin dependent and reduced in rats with defective hepatic insulin signaling.

**Development of NAFLD**

So if these processes are so highly regulated and fine-tuned, why is NAFLD now emerging as a global pandemic? There is no one answer. The increase in NAFLD prevalence with modernization implicates lifestyle factors: we consume more calories than we expend. Obese patients with NAFLD consume more calories than healthy lean individuals (Wehmeyer et al., 2016). Some have implicated a specific increase in sugar consumption (Bray and Popkin, 2014). Sugars, especially fructose, can activate programs of lipogenesis that further exacerbate NAFLD. Fructose is metabolized almost exclusively by the liver, and therefore ingested fructose is funneled into the liver and mostly metabolized to triglycerides by DNL (Herman and Samuel, 2016). The development of hepatic insulin resistance, in which insulin activation of glycogen synthase is impaired, would also be expected to redirect glucose into lipogenic pathways and further promote NAFLD. Consistent with this hypothesis, mice lacking glycogen synthase had hepatic insulin resistance but increased lipogenesis and NAFLD (Irimia et al., 2017). The presence of skeletal muscle insulin resistance can also promote increased hepatic DNL and hypertriglyceridemia by diverting ingested glucose away from skeletal muscle glycogen synthesis and into the liver for hepatic triglyceride synthesis (Flannery et al., 2012; Petersen et al., 2007). Gut microbiota have also been hypothesized to play a role in numerous disease processes, and specific genera (e.g., bacteroides and ruminococcus) have been associated with steatohepatitis and fibrosis, respectively (Boursier et al., 2016).

And, of course, there are genetic factors. The polymorphisms in PNPLA3 are the best studied in this regard. A common SNP (rs738409, I148M) in the lipid droplet protein patatin-like phospholipase domain-containing protein 3 (PNPLA3, also called adiponutrin) has been associated with NAFLD and fibrosis (Romeo et al., 2008; Singh et al., 2014). PNPLA3 has dual functions as a triacylglycerol hydrolase and as an acylglycerol transacylase (Kumari et al., 2012), but the mechanism by which this polymorphism—which attenuates the hydrolase activity (Pingitore et al., 2014)—increases liver fat is still unclear. Overexpression of mutant PNPLA3 in mice had mixed effects, including a decrease in hepatocyte TAG hydrolysis and an increase in enzymes regulating DNL (Li et al., 2012) (though humans with this isoform do not have increases in DNL; Mancina et al., 2015). Genetic deletion of this enzyme failed to induce NAFLD in mice (Basantani et al., 2011; Chen et al., 2010), while a PNPLA3 ASO decreased hepatic fatty acid esterification and protected fat-fed rats from NAFLD, PKCε activation, and hepatic insulin resistance (Kumashiro et al., 2013). Thus, while the association between PNPLA3 and NAFLD is clear, the mechanism underlying the development of NAFLD requires further study.

Other loci have been linked to NAFLD. Polymorphisms in transmembrane 6 superfamily member 2 (rs58542926) have also been associated with NAFLD (Mahdessian et al., 2014). The protein may regulate cholesterol metabolism (Fan et al., 2016; Smagris et al., 2016) and the incorporation of polyunsaturated fatty acids into hepatic triglyceride (Luukkonen et al., 2017), but the exact mechanism by which this polymorphism leads to NAFLD remains unclear. A polymorphism (rs641738) that decreases expression of membrane-bound O-acetyltransferase domain containing 7-transmembrane channel-like 4 (MBOAT7-TMC4) was associated with increased liver lipid content and worsening liver histology (Luukkonen et al., 2016a; Mancina et al., 2016). MBOAT7-TMC4 is found on intracellular membranes such as ER, mitochondria, and lipid droplets and is thought to function as a lysophospholipid acyltransferase,
specifically regulating the incorporation of arachidonic acid into phosphatidylinositol (Gijón et al., 2008). This polymorphism is also associated with fibrosis in alcoholic liver disease (Buch et al., 2015) and chronic hepatitis C (Thabet et al., 2016), suggesting that this pathway could contain therapeutic targets for several liver diseases. Multiple polymorphisms in ApoC3 (Peter et al., 2012; Petersen et al., 2010; Zhang et al., 2016) associated with NAFLD may increase plasma ApoC3 concentrations, which in turn inhibits lipoprotein lipase activity, leading to fasting and postprandial hypertriglyceridemia and predisposing lean individuals to NAFLD and insulin resistance. Less common and more subtle genetic causes have also been identified in pathways that regulate glucose metabolism (e.g., rs1260326 in glucokinase regulatory protein; Santoro et al., 2012). Polymorphisms that decrease expression of the monocarboxylate transporter 4 (MCT4) (Nazare et al., 2017) have been linked with NAFLD (Fabbri et al., 2015). A predominant view has been that VAT (or, more focused discussion (as in the recent review by Cuthbertson et al., 2004). Non-obese subjects with NAFLD are at markedly higher risk for NAFLD: it is slightly higher in whites and Hispanics than in blacks and higher in white males than white females (Browning et al., 2004). Non-obese subjects with NAFLD are at markedly higher cardiovascular risk (Yoshitaka et al., 2017). In a Japanese cohort, the adjusted hazard ratio for cardiovascular disease was ~10-fold higher in non-obese patients with NAFLD compared to those without NAFLD (Yoshitaka et al., 2017). Better strategies and tools are required to identify and treat these at-risk individuals.

**Lipid-Induced Insulin Resistance**

Our understanding of the mechanisms by which NAFLD causes hepatic insulin resistance is informed by the mechanisms for lipid-induced muscle insulin resistance. Several studies observed that ectopic, intramyocellular lipid (IMCL) was closely associated muscle insulin resistance in healthy, young, sedentary lean individuals (Krssak et al., 1999) and non-obese, non-diabetic, but insulin-resistant adults (Perseghin et al., 1999) and children (Sinha et al., 2002). Experimentally, insulin resistance acutely induced by lipid infusions is attributed to impaired insulin-stimulated lipolysis. This changing view of VAT reflects a growing understanding of the heterogeneity of obesity itself. We consider several points to better place the specific role of VAT and more general role of adipocyte function in the context of insulin resistance and NAFLD. Though rates of VAT lipolysis are increased in obesity, subcutaneous adipose tissue—especially from the upper body—quantitatively accounts for the majority of fatty acids delivered to the liver (Jensen, 2008; Nielsen et al., 2004). And intrahepatic lipid content, not VAT mass, better relates to measures of hepatic insulin sensitivity (Fabbri et al., 2009), even in patients with marked obesity (Magkos et al., 2010). Removal of visceral adipose tissue alone (Fabbri et al., 2010b) or in conjunction with bariatric surgery does not significantly impact key metabolic parameters (Andersson et al., 2017; Fabbri et al., 2010b). Though Asians have more VAT at any given BMI than other races (Kadowaki et al., 2006; Nazare et al., 2012), the association between VAT and hepatic lipid content was similar across races (Nazare et al., 2012). The tendency for higher VAT mass in Asian populations may have genetic causes. Discrete loci may influence obesity (Wen et al., 2016) and diabetes (Imamura et al., 2016) in Asian populations, and further studies could establish if these loci influence subcutaneous adipose tissue function. Aging also impairs subcutaneous adipose tissue function, possibly due to the accumulation of senescent adipocytes and impaired pre-adipocyte development, with increases in ectopic lipid accumulation in VAT, liver, and skeletal muscle (Palmer and Kirkland, 2016). In a group of weight-stable patients followed over 10 years, an increase in VAT mass (reflecting ectopic lipid accumulation) was associated with the development of a metabolically unhealthy phenotype (Hwang et al., 2015). Impaired expansion of subcutaneous adipose tissue may also account for non-obese subjects with NAFLD. Globally, the rates of NAFLD in non-obese patients average between 10% and 30% in both Western and Eastern countries (Kim and Kim, 2017). There are modest gender and racial/ethnic differences in the prevalence of non-obese NAFLD: it is slightly higher in whites and Hispanics than in blacks and higher in white males than white females (Browning et al., 2004). Non-obese subjects with NAFLD are at markedly higher cardiovascular risk (Yoshitaka et al., 2017). In a Japanese cohort, the adjusted hazard ratio for cardiovascular disease was ~10-fold higher in non-obese patients with NAFLD compared to those without NAFLD (Yoshitaka et al., 2017). Better strategies and tools are required to identify and treat these at-risk individuals.
Patients with T2D (Cline et al., 1999); and lean, normoglycemic, glucose transport into muscle (Dresner et al., 1999; Roden et al., 1996). Numerous studies delineated the mechanistic links between accumulation of a specific lipid metabolite, diacylglycerol (DAG), and impaired insulin-stimulated muscle glucose transport. In rodents, lipid infusion and high-fat feeding increased muscle DAG, and impaired insulin-stimulated muscle glucose transport. These studies support a mechanistic model in which muscle DAG accumulation activates PKCε, which impairs the direct action of insulin at hepatic IRTK, ultimately limiting the ability of insulin to promote skeletal muscle glucose transport and glycogen synthesis.

Cellular and Molecular Mechanisms of Hepatic Insulin Resistance

Though multiple models have been proposed for the development of hepatic insulin resistance in NAFLD (reviewed in Samuel and Shulman, 2012), a substantial body of work supports the role of DAG accumulation and PKCe activation in impairing hepatic insulin action. Briefly, studies in patients with severe generalized lipodystrophy demonstrated that ectopic lipid accumulation in liver and skeletal muscle was associated with severe hepatic and muscle insulin resistance despite the absence of adipose tissue (Petersen et al., 2002). Leptin therapy reduced calorie intake, resolved hepatic steatosis, and improved hepatic insulin action (Petersen et al., 2002). Lipodystrophic mice have a similar phenotype, and fat transplantation rescued these mice by allowing a redistribution of lipids from ectopic sites to transplanted adipose tissue and normalization of insulin action (Kim et al., 2000). Similarly, mice overexpressing LpL in the liver develop hepatic steatosis and liver-specific insulin resistance (Kim et al., 2001). In rats and mice, short-term high-fat diets lead to hepatic steatosis and hepatic insulin resistance without muscle lipid accumulation or peripheral insulin resistance. These studies demonstrate that ectopic lipid in the liver is specifically associated with hepatic insulin resistance and dissociate hepatic insulin resistance from obesity and visceral adiposity.

In fat-fed rats, the increase in hepatic DAG content activates PKCe, the primary PKC isoform in liver, and also a novel PKC, like PKCθ (Qu et al., 1999; Samuel et al., 2004). DAG-mediated PKCe activation is associated with decreased insulin activation of IRTK (Samuel et al., 2007) (Figure 2). Lowering PKCe expression protected rats from lipid-induced hepatic insulin resistance and preserved IRTK activity without altering hepatic DAG and tri-glyceride content (Samuel et al., 2007). Similarly, Prkce−/− mice are protected from diet-induced insulin resistance following 1 week of high-fat feeding despite increases in liver lipid content.
Together, these data support a model for hepatic insulin resistance (Raddatz et al., 2011). Recently, Petersen et al. identified patients undergoing bariatric surgery (Kumashiro et al., 2011). et al. studied determinants of insulin resistance in a cohort of patients undergoing bariatric surgery and reported increases in specific lipid metabolites (species of fatty acids, ceramides, and TAGs), including specific diacylglycerol species in association with hepatic insulin resistance (e.g., JNK1 activation, ceramide content, etc.). Magkos et al. also demonstrated that hepatic DAG content (but not hepatic ceramide content) was the best predictor of hepatic insulin resistance in obese humans (Magkos et al., 2012). Luukkonen et al. performed lipidomic analyses in liver samples of patients undergoing bariatric surgery and reported increases in specific lipid metabolites (species of fatty acids, ceramides, and TAGs), including specific diacylglycerol species in association with hepatic insulin resistance (Luukkonen et al., 2016b). And most recently, Ter Horst et al. have also shown that cytosolic diacylglycerol content and increased PKCe activity are related to hepatic insulin sensitivity in obese individuals undergoing bariatric surgery (Ter Horst et al., 2017).

**Therapies to Target Metabolic Features of NAFLD and Hepatic Insulin Resistance**

Based on this mechanistic view of the pathogenesis of NAFLD and NAFLD-associated hepatic insulin resistance, the following section summarizes possible therapies for NAFLD and NAFLD-associated hepatic insulin resistance (Figure 3). NAFLD is a common antecedent for both metabolic and liver disease, and our goal is to highlight therapies that can reverse NAFLD to treat both conditions. Some of the therapies also have the potential to limit later metabolic and liver complications, such as cardiovascular disease and liver fibrosis.

**Clinically Established Therapies**

**Weight Loss: Diet.** Most patients with NAFLD, hepatic insulin resistance, and T2D will benefit from weight loss. Weight loss addresses the root causes of insulin resistance, namely ectopic lipid accumulation. Petersen et al. first reported that a moderate caloric restriction (~1,200 kcal/day) decreased body weight by ~10% but was sufficient to reduce hepatic lipid content, normalize hepatic insulin responsiveness, and “reverse” T2D (Petersen et al., 2005). These results have been replicated by other hypocaloric feeding studies (Lazo et al., 2010; Lim et al., 2011). Very-low-calorie diets (e.g., Optifast or LighterLife) can also quickly improve NAFLD in the span of several weeks (Baldry et al., 2017; Lewis et al., 2006), but are not sustainable indefinitely. Specific dietary programs (e.g., Mediterranean diet; Soft and Casini, 2014) have also been reported to be beneficial. Overall, the degree of weight loss achieved is probably the best indicator for the resolution of NAFLD/NASH (Vilar-Gomez et al., 2015). Attempts to enhance weight loss with orlistat did not specifically improve liver histology in human subjects (Harrison et al., 2009).

Aerobic exercise can have profound impacts on insulin sensitivity, but its role in treating NAFLD remains unclear. Skeletal muscle glucose transport is activated by insulin-independent mechanisms in response to exercise and aerobic conditioning. That is, myocellular mechanisms (e.g., AMPK) activated by exercise bypass the block (IRKT → IRS-1 tyrosine phosphorylation) in insulin signaling to enhance muscle glucose uptake and potentially re-establish the normal disposal of dietary glucose into muscle glycogen. In insulin-resistant subjects, a single session of aerobic exercise augmented muscle glucose transport activity and insulin-stimulated muscle glycogen synthesis (Perseghini et al., 1996). A single bout of elliptical training increased postprandial muscle glycogen synthesis and reduced hepatic DNL without altering plasma insulin concentrations in healthy, young, lean individuals with muscle insulin resistance, emphasizing the importance of altered substrate flux in driving hepatic DNL and NAFLD (Rabel et al., 2011). Even short (~6 min) bursts of exercise before meals can significantly improve the diurnal glucose excursion (Francois et al., 2014). However, data supporting exercise to treat NAFLD are limited. Hyperphagic Otsuka Long-Evans Tokushima rats that are prone to developing NASH on a Western diet only show modest improvements in inflammation and fibrosis with 12 weeks of exercise training (Linden et al., 2016). Inactive obese patients who were randomized to several aerobic exercise programs also had modest reductions in liver fat, independent of weight changes (Keating et al., 2015). Aerobic exercise improves muscle insulin sensitivity and decreases DNL, but we need more data to judge the efficacy of exercise prescriptions for NAFLD.

**Weight Loss: Bariatric Surgery.** Bariatric surgery has emerged as the most effective treatment for obesity and related conditions, including T2D and NAFLD. Klein et al. examined liver histology in obese subjects before and 1 year after Roux-en-Y gastric bypass (RYGB) surgery. Patients had a marked loss of body weight (~30%) and metabolic improvements (~30% decrease in EGP, 40% decrease in VLDL secretion, and ~50% decrease in palmitate turnover). Histological liver steatosis and expression of some genes associated with inflammation improved. However, actual histological improvements in inflammation and fibrosis were not evident (Klein et al., 2006). Mattar et al. (2005) performed a similar study in subjects undergoing RYGB. With a greater interval between assessments, they did observe demonstrable improvement in inflammation and fibrosis. Sleeve gastrectomy has recently surpassed RYGB as the most common bariatric procedure performed in the United States (Khorgami et al., 2017) and can resolve steatosis, inflammation, and fibrosis (Billeter et al., 2016; Froylich et al., 2016).

Longer-term studies have demonstrated that the metabolic effects of bariatric surgery persist for an extended period. A 5-year follow-up of obese patients randomly assigned to...
medical therapy or bariatric surgery showed that bariatric surgery improved diabetes control over the 5-year period (Schauer et al., 2017). But these results are not universal. A retrospective analysis of a larger cohort of patients undergoing sleeve gastrectomy found weight regain at 3 and 5 years after surgery and relapse of diabetes in a significant number of patients (e.g., 50% in complete remission at 1 year versus 20% at 5 years; Golomb et al., 2015). To summarize, bariatric surgery offers the greatest weight loss and best chances for resolution of T2D. Bariatric surgery is not available or appropriate for all patients with NAFLD and, in some patients, may not result in resolution of NASH.

Figure 3. Potential Targets to Treat NAFLD and Hepatic Insulin Resistance
Putative targets to treat NAFLD and hepatic insulin resistance. Some therapeutic pathways (green boxes) broadly regulate metabolic pathways. Other therapeutic targets (purple boxes) are specific enzyme targets in lipid synthetic pathways. While many therapeutic targets indirectly increase energy expenditure, mitochondrial uncouplers (red boxes) directly increase cellular energy expenditure, decreasing cellular DAG and mitochondrial acetyl CoA, which increase insulin signaling and decrease gluconeogenesis. White lines show pathways that have been reported to decrease cellular DAG content and/or acetyl CoA concentration. Therapies that improve NAFLD/NASH are labeled with a blue dot. Therapies that improve insulin sensitivity are labeled with an orange dot. Clinical trials have shown the efficacy of weight loss, bariatric surgery, GLP1 analogs (liraglutide), and PPARγ agonists (rosiglitazone and pioglitazone). Current clinical investigation has explored the potential for PPARα/δ dual agonists (elafibranor), FXR agonists, FGF21 analogs (LY2405319 and PF-052313023), and SCD1 inhibitors (Aramachol). Preclinical studies have shown possible efficacy of dual GLP1/GCGR agonists, intestinal FXR antagonists, and inhibitors against MPC (MSDC-0602), ACC1/2 (ND-630), MGAT1 (MOGAT AS0), DGAT2, and glucagon-T3 hybrids (not depicted). Preclinical studies have also shown efficacy for liver-targeted mitochondrial uncoupling agents (CRMP) and other agents that increase cellular energy expenditure (e.g., salsalate, TTA, and niclosamide).
Incretin-Based Therapies. Enthusiasm for incretin-based therapies has been high since they were first approved in 2005. The available analogs all promote modest weight loss, but only liraglutide has been shown to be effective in treating NASH (Armstrong et al., 2013). The recent small (~50 total subjects) Liraglutide Safety and Efficacy in Patients with Non-alcoholic Steatohepatitis (LEAN) study demonstrated that patients with NASH that were blindly randomized to 48 weeks of liraglutide were more likely to have resolution of NASH. As with many clinical trials evaluating NASH treatments, demonstrating histological remission was harder to establish. Many patients had improvement in steatosis and ballooning, but not inflammation or fibrosis. Patients treated with liraglutide were less likely to have progression of fibrosis, however. Validation in larger trials is necessary.

The mechanisms by which incretins improve NAFLD and NASH are not entirely clear. Much of the beneficial effects can be attributed to the decrease in appetite, which is probably regulated by CNS GLP1 action. The central action of GLP1 may also have other effects: promoting increased energy expenditure, activating brown adipose tissue activation, and decreasing white adipose lipid synthesis (Lockie et al., 2012; Sisley et al., 2014). However, in the LEAN trial, among the ~25 patients treated with liraglutide, the reductions in weight and plasma glucose concentrations were similar among those with improvement in liver histology (“responders”) versus those without (“non-responders”), suggesting that part of the beneficial effects of GLP1 analogs may be weight independent (Armstrong et al., 2013). GLP1 analogs may also act to decrease hepatic glucose production (Seghieri et al., 2013) and possibly decrease hepatic DNL (Armstrong et al., 2016). Though some have proposed that GLP-1 has direct effects on hepatocytes, GLP-1 receptors have not been conclusively identified on hepatocytes and possible modes of GLP-1 action on the liver involve modulation of islet hormones and/or neural regulation of hepatocyte metabolism (Jin and Weng, 2016).

Future development of incretin-based therapies may involve dual GLP1/glucagon agonists. Initial interest in this class of molecules was fueled by the finding that oxyntomodulin, another product of preproglucagon, activated both GLP1R and glucagon receptors (GIP-Rs) demonstrated efficacy in reducing food intake, and PPARs in patient with diabetes. A larger trial assessing the efficacy of pioglitazone in nondiabetic patients with NASH failed to achieve the pre-specified level of significance. Nonetheless, pioglitazone did improve several discrete metrics of hepatic inflammation (Sanyal et al., 2010). The benefits of pioglitazone may be most evident in patients with diabetes. A larger trial assessing the efficacy of pioglitazone in nondiabetic patients with NASH failed to achieve the pre-specified level of significance. Nonetheless, pioglitazone did improve several discrete metrics of hepatic inflammation (Sanyal et al., 2010). The benefits of pioglitazone (including reductions in cardiovascular risk) need to be weighed against the known side effects: weight gain, fluid retention, and osteoporotic fracture (Viscoli et al., 2017).

Efforts to leverage other PPARs in treating metabolic diseases have had mixed results. While PPARγ agonists do not correct NAFLD or NASH (Fabbri et al., 2010a; Fernández-Miranda et al., 2008), novel agonists that target both PPARγ and PPARβ/δ appeared effective in treating diabetes and hyperlipidemia, but development of these drugs was halted due to adverse events (Wright et al., 2014). Recent efforts have focused on developing dual agonists against PPARα and PPARβ/δ. The PPARα effects may promote fatty acid oxidation (Pawlak et al., 2015), while the PPARβ/δ effects possibly decrease DNL and suppress inflammation (Bojic and Huff, 2013; Staels et al., 2013). One such agent, elafibranor (GFT505), improved diet-induced NASH in rodents (Staels et al., 2013). Human studies demonstrated some improvement in hepatic and peripheral insulin sensitivity (Cariou et al., 2013). Longer-term studies have shown modest improvements in NASH, as well as modest improvements in insulin resistance and dyslipidemia (Ratziu et al., 2016). Notably, elafibranor did not cause weight gain, though there was an increase in serum creatinine. Further studies of these agents are needed.
**Novel and Emerging Targets**

**Mitochondrial Pyruvate Carriers.** Mitochondrial pyruvate transport is regulated by two key related proteins, mitochondrial pyruvate carrier 1 and 2, which form a transport complex on the inner mitochondrial membrane (Bricker et al., 2012; Herzig et al., 2012). These proteins were discovered to be inhibited by TZD compounds and putatively mediate some of the insulin-sensitizing effects of these drugs; decreased mitochondrial pyruvate oxidation may promote AMPK-mediated muscle glucose uptake (Divakaruni et al., 2013). Liver-specific deletion of either MPC1 (Gray et al., 2015) or MPC2 (McCommis et al., 2015) did not alter glucose production on a C57BL/6 background where the block in MPC was bypassed with flux into the mitochondria as alanine and mitochondrial alanine transaminase. In contrast, liver-specific MPC2 deletion does lower fasting plasma glucose concentrations in diabetic models (db/db mice or streptozotocin-treated diabetic mice), supporting the development of this system as a drug target (McCommis et al., 2015).

Novel PPARγ-sparing TZD compounds have been developed that inhibit MPCs. One of these compounds, MSDC-0602, improved insulin sensitivity in obese mice, with improvements in hepatic, adipose, and muscle insulin signaling and action (Chen et al., 2012). These improvements occurred without changes in body weight or liver triglyceride content. In a separate set of studies, MSDC-0602 was tested in mice fed a 40% high-fat diet supplemented with 20% fructose and 2% cholesterol, a diet that can lead to hepatic inflammation (McCommis et al., 2017). Though MSDC-0602 did not affect liver triglyceride content, it did protect against some histological changes associated with NASH (ballooning and fibrosis). MSDC-0602 may impact stellate cell activation, suggesting that mitochondrial pyruvate metabolism has signaling roles. The development of MPCs as a therapeutic target will need to carefully consider other potential functions. For example, MPC is important for glucose-stimulated insulin secretion. And loss of MPC may be associated with oncogenesis, chemo-resistance, and poor survival in patients with some solid tumors (Schell et al., 2014; Zhong et al., 2015).

**Acetyl-CoA Carboxylase Inhibitors.** Acetyl-CoA carboxylase catalyzes carboxylation of acetyl-CoA into malonyl CoA (Figure 2). ACC1, a predominantly cytoplasmic isoform highly expressed in liver and adipose, catalyzes this committed step in DNL (Savage et al., 2006). In contrast, malonyl-CoA produced by ACC2, a slightly larger (280 versus 265 kDa) mitochondrial isoform highly expressed in skeletal and cardiac muscle, inhibits CPT1 and decreases mitochondrial lipoxidation (Savage et al., 2006). The regulation of ACC activity is complex, involving phosphorylation (e.g., AMPK and PKA inhibit ACC), allosteric regulation (citrate promotes while palmitate inhibits ACC activity) (Hunkeler et al., 2016), and protein-protein interaction (MIG-12-mediated polymerization of ACC enhances activity) (Kim et al., 2010). However, coordinated activation of ACC promotes lipid storage by both stimulating lipogenesis and inhibiting lipid oxidation.

Thus, ACC is an intriguing therapeutic target. ACC2 knockout mice were reported to be protected from weight gain on a high-fat diet with decreases in liver triglyceride associated with improvements in hepatic insulin signaling and action (Abu-Elheiga et al., 2012). However, this phenotype was not replicated in other ACC2-deficient strains (Hoehn et al., 2012; Olson et al., 2010), possibly due to differences in background strain or other unrecognized factors (Hoehn et al., 2012). Liver-specific ACC1 knockout mice have decreased liver triglyceride but without any changes in glucose metabolism (Mao et al., 2006). In contrast, liver-specific ACC1/2 double-knockout mice were prone to steatosis, a surprising phenotype attributed to a shift in fuel utilization with a decrease in lipid oxidation and increase in glycolysis (Chow et al., 2014). In rats, synthetic ASOs targeting both ACC1 and ACC2 were effective in reversing high-fat-diet-induced hepatic insulin resistance, with evidence for both decreased hepatic lipogenesis and increased hepatic lipid oxidation (Savage et al., 2006). Consistent with the DAG-PKCε hypothesis of hepatic insulin resistance, these changes were associated with decreases in liver diacylglycerol content and PKCε activation and improved hepatic insulin signaling.

Several novel small molecule inhibitors of ACC have been designed (Harwood et al., 2003; Tong and Harwood, 2006). Chemical inhibitors of ACC are designed to (1) compete with acetyl-CoA, (2) inhibit the carboxy-transferase reaction, or (3) inhibit the biotin-carboxylation activity, which also may inhibit polymer formation. ND-630 acts by this third mechanism and is a potent inhibitor of ACC1 and 2 (Harriman et al., 2016). This compound was shown to be effective in acutely inhibiting ACC activity in liver and muscle, increasing hepatic lipid oxidation. With chronic treatment, ND-630 was safe and effective in decreasing hepatic and plasma lipid concentration and improving glucose metabolism in both high-sucrose- and high-fat-fed Sprague-Dawley rats as well as diabetic ZDF rats (Harriman et al., 2016). But these results are not generalizable to ACC inhibitors, as some compounds appear to worsen glucose intolerance (Bourbeau et al., 2013). Thus, the mechanism of inhibition is important to the therapeutic efficacy of ACC inhibitors. Additionally, ACC inhibition could lead to accumulation of mitochondrial acetyl-CoA by decreasing DNL and increasing lipid oxidation. Increased acetyl-CoA could allosterically activate pyruvate carboxylase and promote hepatic gluconeogenesis (Perry et al., 2015a), thereby counteracting the improvements in hepatic insulin sensitivity.

**SCD1.** Stearoyl coenzyme A desaturase 1 (SCD1) is responsible for converting stearoyl-CoA (18:0 fatty acyl-CoA) to oleoyl CoA (18:1 fatty acyl-CoA). SCD1 knockout mice were protected from diet-induced obesity and glucose intolerance (Ntambi et al., 2002). However, this phenotype was attributed to altered skin integrity and increased energy expenditure (Sampath et al., 2009). Liver-specific SCD1 knockout mice still developed NAFLD on a high-fat diet, but did have decreased lipogenesis on a high-carbohydrate diet and were protected from the development of NAFLD, possibly due to increased oxidation of carbohydrates to support thermogenesis (Miyazaki et al., 2007). SCD1 ASO therapy protected mice against NAFLD on a high-fat diet with several changes associated with increased energy expenditure (Jiang et al., 2005). This was associated with improvements in hepatic insulin sensitivity (Gutiérrez-Juárez et al., 2006), SCD1 may be a promising target for NAFLD and mechanistically may lead to increased energy expenditure.

Several SCD1 inhibitors have been developed, though clinical data are sparse. Aramachol, a fatty acid-bile acid conjugate, is an SCD1 inhibitor that has been tested in a phase 2 trial (Safadi et al., 2014). While this drug was effective in decreasing hepatic lipid content, there was no alteration in body weight, glucose...
metabolism, or insulin sensitivity (no changes in fasting plasma glucose or insulin concentrations). SCD1 inhibition may still have a role as a potential cancer therapy, though concerns over some pro-inflammatory changes will require a cautious approach to development of this class (Brown and Rudel, 2010). Moreover, the associations between SCD1 and energy metabolism merit further investigation to determine if these effects will translate to humans.

**MGAT.** Monoacylglycerol acyltransferase (MGAT) enzymes comprise a family of three genes that encode enzymes that catalyze the acylation of both monoacylglycerol and diacylglycerol to form DAG and TAG, respectively. This pathway complements diacylglycerol synthesis via the glycerol phosphate pathway and is thought to be very active in enterocytes but upregulated in NAFLD in rodents and humans (Hall et al., 2012). MGAT1 and 2 are active in rodents. MGAT3 is active in humans and also has diacylglycerol transferase activity when 2-monoclyglycerol concentrations are low (Shi and Cheng, 2009). High-fat feeding increases hepatic MGAT1 expression in rodents and MGAT3 expression is associated with NAFLD in obese humans. MGAT1 ASO decreased MGAT1 expression, though with minimal decreases in overall MGAT activity (Hall et al., 2014). MGAT1 ASO decreased liver triglyceride content in mice fed a 40% high-fat/fructose and cholesterol diet, but not in mice fed a 60% high-fat diet (Hall et al., 2014; Soufi et al., 2014). Surprisingly, diacylglycerol content was higher with MGAT1 ASO in both diet groups. Nonetheless, MGAT1 ASO normalized glucose tolerance, decreased PKCε activation, and improved hepatic insulin signaling (Hall et al., 2014). MGAT1 ASO was not effective in preventing inflammatory changes in mice fed the high-fat/fructose and cholesterol diet (Soufi et al., 2014). Chemical inhibitors of MGAT2 have been shown to prevent diet-induced obesity and hepatic steatosis, though this is likely linked to decreased food intake (Okuma et al., 2015a, 2015b). Interestingly, the decrease in food intake was only evident in high-fat-fed rodents and associated with increased incretin hormones, suggesting an interaction between enteric MGAT2 and feeding behavior. It is unknown whether targeting MGAT3 will be effective in treating humans. MGAT3-specific inhibitors have been designed and preliminary studies in transgenic mice expressing MGAT3 have demonstrated efficacy in vivo, though further phenotypic characterization has not been reported (Huard et al., 2015).

**DGAT2.** Acyl-CoA:diacylglycerol acyltransferase (DGAT), the enzyme that acylates diacylglycerols into triglycerides, is not an obvious therapeutic target but may emerge as a potentially useful one. There are two isoforms, DGAT1 and 2, encoded by discrete genes. Both are widely expressed in a number of tissues, including liver and WAT. DGAT1 is also highly expressed in the small intestine. DGAT1 knockout mice are protected from diet-induced obesity and insulin resistance. This phenotype is associated with alterations in energy balance, which are mostly attributed to reduced enteric fat absorption. DGAT2 deficiency is embryonic lethal. However, decreasing hepatic and adipose DGAT2 expression with specific ASOs lowers diacylglycerol content (and PKCε activity) by inhibiting lipogenesis and reverses diet-induced hepatic insulin resistance (Choi et al., 2007). Conversely, transgenic overexpression of hepatic DGAT2 increases hepatic TAG and DAG content ~2.5- to 3-fold and hepatic ceramide content by ~10-15% and is associated with hepatic insulin resistance (Jornayvaz et al., 2011). Thus, DGAT2 exerts a paradoxical effect on hepatic DAG content: inhibition decreases DAG and PKCε activity while overexpression increases DAG content and PKCε activity. It is possible that transient increases in early lipid intermediates following DGAT inhibition (e.g., fatty acyl-CoAs) may suppress the lipogenic pathway (Choi et al., 2007).

DGAT1 inhibitors are currently being investigated as potential therapies. In rodents, DGAT inhibition appears to primarily impact intestinal lipid absorption with possibly associated increases in intestinal fatty acid oxidation and GLP-1 secretion (Liu et al., 2015; Maciejewski et al., 2013; Schober et al., 2013). Preclinical studies suggest that DGAT inhibitors prevent weight gain, hepatic steatosis, and insulin resistance (Cao et al., 2011; Tomimoto et al., 2015). Clinical studies show that DGAT1 inhibition may be an effective treatment in familial chylomicronemia syndrome. Though many subjects experience some gastrointestinal side effects, these were mild and tolerable (Meyers et al., 2015). DGAT2 is not thought to impact intestinal lipid handling, and thus DGAT2 inhibitors may be better tolerated in many patients with NAFLD. Development and clinical trials of specific DGAT2 inhibitors are currently underway (Futatsugi et al., 2015; Imbriglio et al., 2015). Interestingly, both MGAT and DGAT activity may also have secondary effects on energy expenditure and thus some of the beneficial effects of inhibitors of these enzyme pathways may involve altering energy balance (Shi and Cheng, 2009).

**Farnesoid X Receptor Agonists.** Farnesoid X receptor (FXR) is a receptor for bile acids, canonically suppressing expression of Cyp7A1, a rate-limiting step in bile acid synthesis. However, FXR also regulates the expression of numerous metabolic pathways, including gluconeogenesis and lipogenesis (Kliewer and Mangelsdorf, 2015). FXR has been developed as a novel drug target. In part, these beneficial effects of FXR agonists may be due to changes in energy balance. For example, the ability of specific bile acids to prevent obesity and glucose intolerance in fat-fed mice is dependent on FXR-mediated activation of thermogenesis (Watanabe et al., 2006). A synthetic FXR agonist was able prevent hepatic inflammation and fibrosis in mice fed an MCD diet (Zhang et al., 2009). FXR agonists may also decrease hepatic DAG by activating diacylglycerol kinases, which reduce cellular diacylglycerol pools (Cai and Sewer, 2013). In a proof-of-concept study, 6 weeks of obeticholic acid, an FXR agonist, was reported to promote mild weight loss, improve insulin sensitivity, and lessen markers of hepatic fibrosis in human subjects (Mudaliar et al., 2013). Longer studies have shown that obeticholic acid promotes mild weight loss and improved liver histology in patients with NAFLD (Neuschwander-Tetri et al., 2015). Despite the improvement in hepatic steatosis, there was an increase in fasting serum insulin concentrations, raising the possibility of worsening insulin resistance (Neuschwander-Tetri et al., 2015). As a significant number of patients experienced pruritus as a side effect, newer non-bile acid FXR agonists have been developed, such as BAR502 (Carino et al., 2017). In mice, BAR502 was effective in reversing obesity in fat-fed mice, with improvement in hepatic steatosis, hepatic inflammation, and glucose intolerance (Carino et al., 2017).

Some of the effects of FXR agonists may be mediated by FGF19 (FGF15 is the rodent ortholog), a protein secreted by
the small intestine in response to bile acids that contributes to the suppression of hepatic Cyp7A1 (Inagaki et al., 2005; Pothoff et al., 2012). But FGF15/19 has additional effects in the liver, such as potentiating glycogen synthesis (Kim et al., 2011) and decreasing expression of gluconeogenic (Pothoff et al., 2011) and lipogenic enzymes (Bhatnagar et al., 2009). Obeticholic acid has been shown to increase serum FGF19 concentrations in humans (Mudalil et al., 2013). However, the therapeutic use of FGF19 itself has been limited by the potential for ectopically produced FGF19 to induce hepatocellular carcinoma (Nicholes et al., 2002). Recently, a novel FGF19 analog (M70 or NGM282) has been designed to selectively activate key metabolic pathways, but not mitogenic pathways (Zhou et al., 2014), and is being developed as a treatment for cholestatic and metabolic disorders (Degrilamo et al., 2016). A phase 2 study of NGM282 in subjects with biopsy-confirmed NASH demonstrated that NGM282 could induce a significant reduction in liver fat and inflammation, though with a 30%–50% increase in plasma LDL concentration (Harrison et al., 2017).

In contrast to the development of FXR agonists, there may also be a role for FXR antagonists in the treatment of metabolic disease. Ileal FXR expression was observed to positively relate to obesity in humans, raising the possibility that intestinal FXR should be inhibited (Jiang et al., 2015). Studies using glycine-β-muricholic acid, a nonhydrolyzable bile acid that antagonizes FXR, demonstrate that it increases energy expenditure in fed and db/db mice, reversing hepatic steatosis and improving glucose and insulin tolerance (Jiang et al., 2015). Ileal FXR inhibition had several effects, including increases in some bile acid species and a decrease in FGF15. However, the investigators hypothesized that ileal FXR regulates synthesis of a specific ceramide species that inhibits browning of adipocytes; C16:0 ceramide “replacement” in glycine-β-muricholic acid-treated mice blocked many of the beneficial effects (Jiang et al., 2015). Thus, inhibition of ileal FXR may increase energy expenditure via reductions of a specific ceramide molecule.

**Thyroid Hormone Mimetics.** Another proposed mechanism by which bile acids may impact hepatocellular energy metabolism is via activation of the G protein-coupled receptor TGR5, which in turn increases deiodinase-2 expression and activation of thyroid hormone. Some TGR5 agonists have been reported to have glucose-lowering (Agarwal et al., 2015; Briere et al., 2015) and lipid-lowering (Zambad et al., 2013) effects in rodents, but the effects on NAFLD have not been reported. TGR5 activation promotes gallbladder filling and thus agonists against TGR5 have the potential to promote gallstone formation. Attempts have also been made to target thyroid hormone receptor-β (TRβ). TRβ-1 is the predominant form expressed in the liver and activation of TRβ has been hypothesized to have potential metabolic benefits in terms of lipid and glucose lowering. Indeed, KB-2115 has been shown to be very efficacious in treating hyperlipidemia (Ladenson et al., 2010). Moreover, KB-2115 and GC-1, another TRβ-specific agonist, both prevented hepatic steatosis in rats fed a high-fat diet (Vatner et al., 2013) and in ob/ob mice (Martagón et al., 2015). However, despite these benefits, neither treatment improved insulin sensitivity due to discrete off-target effects (Vatner et al., 2013). A new approach to leverage hepatic thyroid hormone action uses a novel glucagon-T3 hybrid molecule (Finan et al., 2016). The presence of a peptidase-resistant glucagon effectively targets the T3 to the liver, where it is presumably released by hydrolysis of a gamma glutamic acid spacer. Glucagon-T3 has marked effects in increasing energy expenditure (without altering food intake), reduction in fat mass, reductions in plasma and hepatic lipid content, and improvements in glucose tolerance. This hybrid molecule exerts these effects through multiple pathways, partly through fibroblast growth factor 21 (FGF21), activation of brown adipose tissue, and directly altering hepatic lipid and glucose metabolism (Finan et al., 2016). Each component of this hybrid appears to mitigate the adverse effects of the partner: by targeting the liver, glucagon-T3 does not cause cardiac or bone toxicity while the T3 component mitigates the glucose-raising effects of glucagon (Finan et al., 2016).

**FGF21.** Therapeutic effects of PPARγ agonists and thyroid hormone agonists are partly attributable to induction of FGF21. FGF21 is a PPARγ target that is primarily produced in the liver, WAT, and exocrine pancreas (Inagaki et al., 2007). FGF21 coordinates the metabolic shift from fed to fasted states; FGF21 regulates hepatic ketogenesis, gluconeogenesis, and adipose lipolysis (Badman et al., 2007; Inagaki et al., 2007). FGF21 action also regulates cellular energy metabolism. Mice lacking hepatic FGF21 are prone to developing glucose intolerance when placed on a high-fat diet (Markan et al., 2014), whereas FGF21 transgenic mice have enhanced glucose tolerance (Zhang et al., 2012). Rodent studies have shown that exogenous FGF21 protects high-fat-fed mice from insulin resistance by increasing cellular energy expenditure independently of brown adipose tissue activation (Camporez et al., 2013; Xu et al., 2009). This effect appears to be mediated centrally via hypothalamic receptors and activation of the sympathetic nervous system (Owen et al., 2014). The increases in energy expenditure are associated with a reduction in hepatic diacylglycerol content, decreased PKCε activation, and improved insulin signaling (Camporez et al., 2013). FGF21 also suppresses WAT lipolysis, another potentially therapeutic effect (Park et al., 2016).

In humans, serum FGF21 concentration is positively associated with obesity and insulin resistance (Zhang et al., 2008). NAFLD is associated with increased activity of the transcription factor cyclic AMP-responsive element-binding protein H (CREBH), which increases expression of FGF21 (Park et al., 2016). Hepatic FGF21 may even be enhanced by fructose metabolism (Dushay et al., 2014). Increased FGF21 may suppress adipose lipolysis and limit hepatic fat accumulation (Park et al., 2016). Though FGF21 is already increased in obese states, preclinical rodent studies suggest that pharmacological supplementation may be beneficial. Several analogs have been evaluated in clinical trials with mixed results. LY2405319, an FGF21 variant, was tested in subjects with T2D. LY2405319 reduced body weight, plasma triglyceride, and cholesterol. However, the impact on plasma glucose and insulin was less clear. PF-052313023, a long-acting FGF21 analog, also decreased body weight and improved plasma lipid profile in subjects with T2D. However, there were also changes in bone turnover markers, possibly due to PPARγ-mediated inhibition of osteoblastogenesis (Wei et al., 2012). A recent phase 2 study demonstrated that a once weekly pegylated FGF21 (BMS-986036) effectively decreases liver fat, serum transaminases, plasma triglyceride, and LDL while increasing adiponectin without any significant
adverse events, paving the way for longer phase 3 studies (Sanyal et al., 2017).

**Liver-Targeted Mitochondrial Uncoupling Agents.** Many of the potential agents discussed above improve hepatic insulin resistance and NAFLD partly by altering cellular energy balance. Altered cellular energy balance is a key feature of other agents that have been reported to decrease liver fat and/or improve hepatic insulin sensitivity, including salsalate (an anti-inflammatory agent; Smith et al., 2016), 1-tripletetradecylthioacetic acid (TTA, a novel fatty acid analog; Lindquist et al., 2017), and glucoraphanin (a compound present in cruciferous vegetables that promotes browning of WAT, increases energy expenditure, and protects rodents from diet-induced insulin resistance; Nagata et al., 2017). Other novel agents have been developed to primarily alter cellular energy expenditure. Niclosamide is an anthelmintic drug that promotes mitochondrial uncoupling. It is orally bioavailable with a primary distribution to liver and kidney and was efficacious in preventing diet-induced obesity in high-fat-fed mice (Tao et al., 2014). This effect was associated with alterations in cellular energy charge, activation of AMPK, and reductions in hepatic DAG content.

However, it is possible to create compounds that will specifically, directly, and safely increase hepatic mitochondrial energy expenditure. We previously demonstrated the efficacy of low doses of the mitochondrial protonophore, 2,4-dinitrophenol (DNP), in preventing steatosis in high-fat-fed rats, with decreased PKCε activation and improved hepatic insulin signaling and hepatic insulin action (Samuel et al., 2004). Though DNP has been used clinically in the past, this compound is not safe for clinical use due to the low therapeutic index. If DNP is modified with a methyl-ester (ME), it remains inactive until activated within hepatocytes. This increases the therapeutic index of DNP-ME 50-fold over DNP. DNP-ME increased hepatic mitochondrial fat oxidation by ~60% and reversed hypertriglycerideremia, hepatic and peripheral insulin resistance, and hyperglycemia in rat models of NAFLD and T2D (Perry et al., 2013). DNP-ME did not alter cellular energy charge, nor did it lead to activation of AMPK; its actions are likely due purely to the induced energy inefficiency of the mitochondria exclusively in liver. Furthermore, correction of liver and muscle insulin resistance was associated with marked reductions in liver and skeletal muscle DAG content with decreased activation of PKCε and PKCζ, respectively. The latter improvements in muscle DAG-PKCζ activity could be attributed to DNP-ME increased in hepatic fat oxidation, leading to reduced VLDL production, reduced plasma triglycerides, and decreased fat delivery to skeletal muscle. Importantly, these improvements occurred independently of any changes in body weight, inflammatory mediators, FGF-21, adiponectin, or hepatic ceramide content (Perry et al., 2013).

Similar effects were seen with a second liver-targeted mitochondrial uncoupling agent, controlled release mitochondrial protonophore (CRMP) (Perry et al., 2015b). Combining DNP into a cellulose-based matrix extends the time required for absorption, resulting in relatively stable plasma DNP concentrations after oral administration. CRMP increases the therapeutic index by 500-fold and, as with DNP, lowers hepatic and muscle lipid (DAG) content and improves insulin hepatic and peripheral sensitivity in numerous rodent models of NAFLD/NASH (Perry et al., 2015b). While CRMP is not “liver specific” by design, the first-pass hepatic uptake largely confines its actions to the liver. CRMP increased the rate of hepatic tricarboxylic cycle flux without changing whole-body energy balance or mitochondrial activity in other tissues. Like DNP-ME, the reductions in plasma triglyceride and improvement in skeletal muscle activity were attributed to CRMP-induced increases in hepatic mitochondrial fatty acid oxidation, resulting in decreased VLDL production and hypertriglycerideremia and reduced delivery and uptake of fat by the skeletal muscle. In rats fed an MCD diet, CRMP treatment reduced hepatic inflammation and reversed hepatic fibrosis. CRMP has also recently been shown to reverse hepatic steatosis and hepatic and peripheral insulin resistance in an A-ZIP/F1 mouse model of severe lipodystrophy (Abulizi et al., 2017). CRMP also decreased several markers of liver inflammation and the unfolded protein response in this lipodystrophic mouse. Furthermore, CRMP, like DNP-ME, reversed hepatic insulin resistance and diabetes with reductions in hepatic DAG-PKCε activity and hepatic acetyl-CoA content, offering further support for the roles of these metabolites in causing hepatic insulin resistance and increased hepatic gluconeogenesis, respectively, in T2D. Taken together, these studies offer proof of concept in support of the development of novel liver-targeted mitochondrial uncoupling agents for the treatment of NAFLD, NASH, and T2D.

**Conclusion**

We face significant challenges in tackling the growing and global epidemic of NAFLD. The widespread prevalence of NAFLD, the attendant risks for metabolic and hepatic complications, and the lack of approved therapies are significant hurdles. But there is a solid and mechanistic foundation with which to tackle this challenge. There are ample data that show that NAFLD is present before the overt onset of either T2D or NASH. In NAFLD, diacylglycerol-mediated activation of PKCε impairs insulin signaling and increases in hepatic acetyl-CoA content, which can mostly be attributed to rates of mitochondrial β-oxidation, exceeding rates of mitochondrial TCA flux, and results in activation of pyruvate carboxylase activity/flux and stimulation of hepatic gluconeogenesis. Subsequent pathogenic changes may also trigger inflammation, hepatocyte damage, and fibrosis. Challenges remain in developing better tools to predict who is at risk for NAFLD (especially in non-obese individuals), non-invasively diagnosing NAFLD, and stratifying those patients at risk for progression. Changes in health policies are needed to decrease the incidence of NAFLD, and regulatory agencies may need to consider NAFLD per se as a treatment indication. But as reviewed above, there are several promising targets for therapy. We are well poised to re-purpose or refine existing drugs to treat NAFLD and develop new agents to tip the balance of hepatic lipid metabolism to decrease NAFLD and prevent or reverse the associated metabolic and hepatic complications.

**ACKNOWLEDGMENTS**

Supported by grants from the NIH (DK-R01 DK 11398401, DK-40936, and DK-45735) and Veteran’s Administration (I01 BX000901). G.I.S. serves on scientific advisory boards for Merck, Novo Nordisk, Celgene, Aegerion, and AstraZeneca; receives investigator-initiated support from Gilead Sciences; and is an inventor on Yale patents for liver-targeted mitochondrial uncoupling.
agents and controlled release mitochondrial uncoupling agents for the treatment of NAFLD, NASH, T2D, and related metabolic disorders.

REFERENCES


inhibition of hepatic acetyl-CoA carboxylase activity increases liver fat and alters global protein acetylation. Mol. Metab. 3, 419–431.


LBO-07 - NGM282, a novel variant of QFG19, significantly reduces hepatic steatosis and key biomarkers of NAFLD: results of a Phase 2, multicenter, randomized, double-blind, placebo controlled trial in biopsy-confirmed NASH patients. J. Hepatol. 66, 592–593.


Please cite this article in press as: Samuel and Shulman, Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases, Cell Metabolism (2017), http://dx.doi.org/10.1016/cmet.2017.08.002


Zhang, Y., Xi, Y., Berglund, E.D., Coate, K.C., He, T.T., Katafuchi, T., Xiao, G., Pothoff, M.J., Wei, W., Yan, W., et al. (2012). The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. eLife 1, e00065.


